Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage

Patent metadata

Field	Value
Publication number	US-11052045-B2
Application number	US-201615383201-A
Country	US
Kind code	B2
Filing date	Dec 19, 2016
Priority date	Sep 19, 2014
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.

First claim

What is claimed is:

1. A method of producing a dried formulated plasma, the method comprising providing:
i) plasma,
ii) one or more physiologically compatible stable acidic substances, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH and is physiologically suitable for addition to plasma being dried or physiologically suitable for subjects into which reconstituted plasma is transfused, wherein when plasma and one or more stable acidic substances are combined, the combination creates a formulated plasma, and
iii) a plasma drying system for drying the formulated plasma
to thereby create a dried formulated plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 and about 0.050 mmol/ml in the plasma.

2. The method of claim 1 , further comprising:
a) combining the plasma with the one or more stable acidic substance to thereby obtain formulated plasma,
b) drying the formulated plasma to obtain dried formulated plasma; and
c) reconstituting the dried formulated plasma with sterile water to produce reconstituted plasma.

3. The method of claim 2 , wherein when said formulated plasma is dried and reconstituted to obtain reconstituted plasma, said reconstituted plasma has a pH of about 6.8 to about 7.6.

4. The method of claim 2 , wherein when combining the plasma with the one or more stable acidic substances, said pH of said plasma is adjusted with said one or more stable acidic substance up to 30 minutes before drying.

5. The method of claim 2 , wherein when combining the plasma with the one or more stable acidic substances, said pH of said plasma is adjusted by adding one or more stable acidic substances immediately prior to or contemporaneously with drying.

6. The method of claim 2 , wherein the pH of the plasma is known prior to addition of said one or more stable acidic substances and the amount of said one or more stable acidic substances to be added plasma is determined based on the known pH of said plasma.

7. The method of claim 2 , wherein citric acid is added to the plasma to increase citrate concentration by 7.4 mM.

8. The method of claim 2 , wherein said formulated plasma has a pH of about 5.5 to about 6.5.

9. The method of claim 2 , wherein von Willebrand factor activity from reconstituted plasma is between about 5 and about 40 percentage points greater than the von Willebrand factor activity obtained from an otherwise identical dried plasma that has not undergone formulation with one or more stable acidic substances.

10. The method of claim 9 , wherein of von Willebrand factor activity from reconstituted plasma is between about 10 and about 35 percentage points greater than the von Willebrand factor activity obtained from an otherwise identical dried plasma that has not undergone formulated with one or more stable acidic substances.

11. The method of claim 2 , wherein said dried formulated plasma is stable at ambient temperature for at least 7 days.

12. The method of claim 11 , further comprising measuring activity of Factors V, VII, VIII and IX or any combination thereof to determine stability of the reconstituted plasma.

13. The method of claim 1 , further comprising the steps of combining the plasma with the stable acidic substances to thereby obtain formulated plasma and drying the formulated plasma with the dryer system to create dried formulated plasma.

14. The method of claim 13 , wherein when said dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstituted plasma exhibits von Willebrand factor activity at least 5 percentage points greater than von Willebrand factor activity obtained from an otherwise identical dried plasma that has not undergone treatment with one or more stable acidic substances.

15. The method of claim 13 , further comprising reconstituting the dried formulated plasma with sterile water only to produce reconstituted plasma.

16. The method of claim 13 , wherein when said dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstituted plasma has a physiological pH.

17. The method of claim 13 , wherein when said spray dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstitution solution is an alkaline solution.

18. The method of claim 1 , wherein when said formulated plasma is reconstituted to obtain reconstituted plasma, the reconstitution solution comprises a substance selected from the group consisting of: sodium bicarbonate, disodium phosphate, and glycine sodium hydroxide.

19. The method of claim 1 , wherein said plasma comprises CPD (citrate phosphate dextrose solution) plasma or is WB (whole blood) plasma.

20. The method of claim 1 , wherein the one or more stable acidic substances is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, glycine hydrogen chloride (glycine-HCl), lactic acid and monosodium citrate.

21. A method of producing spray dried formulated plasma, the method comprising:
a) contacting i) plasma with ii) one or more spray dry stable acidic substances (SDSAS), wherein said one or more SDSAS is an acid or acidic salt that effectuates a pH and is physiologically suitable for addition to plasma being spray dried or physiologically suitable for subjects into which reconstituted plasma is transfused, to thereby create a formulated plasma so that the pH of formulated plasma is between about 5.5 and 7.2, and
b) spray drying the formulated plasma to thereby obtain spray dried formulated plasma.

22. The method of claim 21 wherein when said spray dried formulated plasma is reconstituted to obtain reconstituted plasma, said reconstituted plasma has a pH of about 6.8 to 7.6.

23. The method of claim 21 wherein when said spray dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstituted plasma has a physiological pH.

24. The method of claim 21 , wherein when said spray dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstitution solution is an alkaline solution.

25. The method of claim 21 , wherein when said spray dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstitution solution comprises a substance selected from the group consisting of: sodium bicarbonate, disodium phosphate, and glycine sodium hydroxide.

26. The method of claim 21 , wherein said plasma comprises CPD (citrate phosphate dextrose solution) plasma or is WB (whole blood) plasma.

27. The method of claim 21 , wherein the SDSAS is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, glycine hydrogen chloride (glycine-HCl), lactic acid and monosodium citrate.

28. The method of claim 21 , wherein when the spray dried formulated plasma is reconstituted to obtain reconstituted plasma, the reconstituted plasma exhibits von Willebrand factor activity at least 5 percentage points greater than the von Willebrand factor activity obtained from an otherwise identical spray dried plasma that has not undergone treatment with a SDSAS.

29. The method of claim 21 , further comprising reconstituting the spray dried formulated plasma with sterile water to produce reconstituted plasma.

30. The method of claim 21 , further comprising reconstituting the spray dried formulated plasma with sterile water only to p

Assignees

• Velico Medical Inc

Inventors

• Liu Qiyong Peter
• Cui Junqing
• Lucien Rud Karly
• Carney Ryan
• Sohn Jihae
• Arya Michelle

Classifications

• A61K9/1688 Primary

  resulting in pure drug agglomerate optionally containing up to 5% of excipient · CPC title

• B65D51/30

  for desiccators · CPC title

• A61K9/1617

  Organic compounds, e.g. phospholipids, fats · CPC title

• B01J19/06

  Solidifying liquids (making microcapsules B01J13/02) · CPC title

• F26B3/06

  the gas or vapour flowing through the materials or objects to be dried (F26B3/14 takes precedence) · CPC title